InspireMD

OverviewSuggest Edit

InspireMD was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes.
Today, InspireMD is a global company headquartered in Boston, MA. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures.

TypePublic
Founded2005
HQTel Aviv-Yafo, ILMap
Websiteinspiremd.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2021)45
Revenue (FY, 2020)$2.5 M(-33%)
Share Price (Dec 2021)$3(+4%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at InspireMD

Marvin Slosman

Marvin Slosman

Chief Executive Officer, Director
Paul Stuka

Paul Stuka

Chairman of the Board
Craig Shore

Craig Shore

Chief Financial Officer
Michael Berman

Michael Berman

Director
Gary Roubin

Gary Roubin

Director
Andrea Tommasoli

Andrea Tommasoli

Senior VP Global Sales & Marketing
Show more

InspireMD Office Locations

InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe)
Tel Aviv-Yafo, IL (HQ)
4 Menorat HaMa'or St
Winsen (Luhe), DE
16 Boschstraße
Show all (2)

InspireMD Financials and Metrics

InspireMD Revenue

Embed Graph
View revenue for all periods
InspireMD's revenue was reported to be $2.49 m in FY, 2020
USD

Revenue (Q1, 2021)

1.0m

Gross profit (Q1, 2021)

106.0k

Gross profit margin (Q1, 2021), %

10.5%

Net income (Q1, 2021)

(3.2m)

EBIT (Q1, 2021)

(3.3m)

Market capitalization (31-Dec-2021)

23.7m

Closing stock price (31-Dec-2021)

3.0

Cash (31-Mar-2021)

44.0m

EV

(19.5m)
InspireMD's current market capitalization is $23.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.0m2.1m3.1m2.8m2.3m1.9m2.8m3.6m3.7m2.5m

Revenue growth, %

(26%)(18%)

Cost of goods sold

3.0m1.4m1.4m2.0m2.6m1.8m2.2m2.6m3.0m2.4m

Gross profit

3.0m694.0k1.7m784.0k(296.0k)102.0k585.0k995.0k756.0k83.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

1.0m2.0m1.1m1.4m1.5m1.6m1.5m193.0k273.0k477.0k685.0k632.0k563.0k540.0k469.0k569.0k640.0k718.0k1.0m1.0m769.0k415.0k1.4m939.0k1.0m313.0k1.0m

Cost of goods sold

640.0k801.0k574.0k547.0k674.0k750.0k625.0k584.0k349.0k514.0k897.0k543.0k497.0k478.0k438.0k495.0k493.0k565.0k714.0k726.0k571.0k488.0k912.0k811.0k739.0k433.0k900.0k

Gross profit

400.0k1.2m564.0k803.0k840.0k802.0k857.0k(391.0k)(76.0k)(37.0k)(212.0k)89.0k66.0k62.0k31.0k74.0k147.0k153.0k293.0k277.0k198.0k(73.0k)442.0k128.0k295.0k(120.0k)106.0k

Gross profit Margin, %

38%60%50%59%55%52%58%(203%)(28%)(8%)(31%)14%12%11%7%13%23%21%29%28%26%(18%)33%14%29%(38%)11%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.1m10.3m17.5m3.3m7.5m3.7m9.4m5.5m12.6m

Accounts Receivable

2.3m1.8m1.9m405.0k643.0k716.0k823.0k476.0k

Prepaid Expenses

72.0k93.0k141.0k75.0k62.0k81.0k87.0k334.0k

Inventories

2.1m1.7m1.6m753.0k500.0k533.0k1.1m1.2m1.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

8.1m7.5m3.4m5.4m2.5m11.4m13.7m9.0m5.0m13.2m9.8m6.5m2.0m885.0k10.5m8.6m6.9m4.8m4.6m6.4m11.2m5.8m4.8m7.2m3.1m13.9m44.0m

Accounts Receivable

614.0k1.8m2.0m1.3m2.1m2.1m1.5m493.0k397.0k719.0k728.0k546.0k432.0k542.0k471.0k451.0k538.0k754.0k916.0k710.0k464.0k861.0k796.0k856.0k416.0k708.0k

Prepaid Expenses

71.0k103.0k89.0k94.0k91.0k144.0k110.0k215.0k138.0k109.0k76.0k62.0k41.0k107.0k21.0k73.0k109.0k53.0k71.0k145.0k66.0k44.0k155.0k63.0k40.0k207.0k

Inventories

1.5m1.9m2.0m2.0m2.0m1.4m1.3m1.5m1.7m1.8m1.2m1.1m511.0k387.0k365.0k329.0k429.0k576.0k517.0k637.0k816.0k1.4m1.2m1.3m1.2m1.4m1.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(14.7m)(7.1m)(9.3m)(25.1m)(15.6m)(8.5m)(8.4m)(7.2m)(10.0m)(10.5m)

Depreciation and Amortization

89.0k69.0k188.0k263.0k241.0k191.0k178.0k152.0k158.0k151.0k

Inventories

(261.0k)317.0k(331.0k)1.2m253.0k(33.0k)(601.0k)(102.0k)(179.0k)

Accounts Payable

(371.0k)(291.0k)737.0k(659.0k)(397.0k)106.0k(290.0k)584.0k(283.0k)(410.0k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2013Q3, 2013Q1, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(4.1m)(6.4m)(3.1m)(9.4m)(14.3m)(3.9m)(6.0m)(13.5m)(20.3m)(5.2m)(9.1m)(12.7m)(2.6m)(4.6m)(6.6m)(2.6m)(4.9m)(6.9m)(2.4m)(3.0m)(5.0m)(3.2m)(5.4m)(7.5m)(2.0m)(4.5m)(3.2m)

Depreciation and Amortization

38.0k52.0k34.0k95.0k146.0k50.0k56.0k122.0k181.0k75.0k135.0k195.0k48.0k95.0k143.0k42.0k84.0k127.0k41.0k79.0k115.0k35.0k73.0k114.0k51.0k88.0k51.0k

Inventories

(51.0k)(233.0k)(238.0k)201.0k250.0k79.0k(89.0k)174.0k695.0k843.0k242.0k366.0k388.0k171.0k71.0k(76.0k)16.0k(104.0k)(283.0k)(313.0k)(84.0k)(149.0k)34.0k(166.0k)231.0k

Accounts Payable

(340.0k)(541.0k)(481.0k)60.0k(65.0k)19.0k(218.0k)(94.0k)(75.0k)(244.0k)(418.0k)(75.0k)(59.0k)686.0k(103.0k)(267.0k)(145.0k)(216.0k)184.0k148.0k128.0k(57.0k)(311.0k)(242.0k)(84.0k)(188.0k)165.0k
show all
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

InspireMD Cybersecurity Score

Cybersecurity ratingPremium dataset

D

61/100

Learn more about our premium products
SecurityScorecard logo

InspireMD Online and Social Media Presence

InspireMD's Trends

Embed Graph

InspireMD News and Updates

November 09, 2021

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-CGuard™ sales generated 24% YoY revenue growth-
November 03, 2021

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA ra…
October 26, 2021

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET
October 13, 2021

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received …
August 10, 2021

InspireMD Announces Strong Second Quarter 2021 Financial Results

Revenue rebound, strong procedural recovery
August 04, 2021

InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET Earnings conference call to be held Tuesday, August 10, 2021, at 8:30 a.m. ET
Show more

 InspireMD Frequently Asked Questions

  • When was InspireMD founded?

    InspireMD was founded in 2005.

  • Who are InspireMD key executives?

    InspireMD's key executives are Marvin Slosman, Paul Stuka and Craig Shore.

  • How many employees does InspireMD have?

    InspireMD has 45 employees.

  • What is InspireMD revenue?

    Latest InspireMD annual revenue is $2.5 m.

  • What is InspireMD revenue per employee?

    Latest InspireMD revenue per employee is $55.2 k.

  • Who are InspireMD competitors?

    Competitors of InspireMD include Biovotion, Elanix Biotechnologies and 19Labs.

  • Where is InspireMD headquarters?

    InspireMD headquarters is located at 4 Menorat HaMa'or St, Tel Aviv-Yafo.

  • Where are InspireMD offices?

    InspireMD has offices in Tel Aviv-Yafo and Winsen (Luhe).

  • How many offices does InspireMD have?

    InspireMD has 2 offices.